임상

HOME > 연구실적 > 임상 > 논문
 
작성일 : 16-03-14 02:37
논문번호 166
논문제목(영문) One-year clinical outcomes of everolimus- versus sirolimus-eluting stents in patients with acute myocardial infarction.
국내외구분 국외 SCI여부 SCI(E)
연구책임자역할 공저자
주저자명 Chen KY
교신저자명 Rha SW
공동저자명 Chen KY, Rha SW, Wang L, Li YJ, Li GP, Choi CU, Park CG, Seo HS, Oh DJ, Jeong MH, Ahn YK, Hong TJ, Kim YJ, Chae SC, Hur SH, Seong IW, Chae JK, Cho MC, Bae JH, Choi DH, Jang YS, Chae IH, Kim HS, Kim CJ, Yoon JH, Ahn TH, Chung WS, Seung KB, Park SJ;
게제년월일 2014-08-09
ISSN 0167-5273
Impact Factor 4.036
학술지명 International journal of cardiology
서지사항 0집 / 176권 / 3호,   페이지(583 - 588)
요약초록문
(Abstract) 입력		 BACKGROUND:
In contrast to many studies comparing everolimus-eluting stent (EES) with paclitaxel-eluting stent (PES), data directly comparing EES with sirolimus-eluting stent (SES) are limited, especially in patients with acute myocardial infarction (AMI).
METHODS:
This study includes 2911 AMI patients treated with SES (n=1264) or EES (n=1701) in Korea Acute Myocardial Infarction Registry (KAMIR). Propensity score matching was applied to adjust for baseline imbalance in clinical and angiographic characteristics, yielding a total of 2400 well-matched patients (1200 receiving SES and 1200 receiving EES). One-year clinical outcomes were compared between the two propensity score matched groups.
RESULTS:
Baseline clinical and angiographic characteristics were similar between the two propensity score matched groups. One-year clinical outcomes of the propensity score matched cohort were comparable between the EES versus the SES groups including the rates of cardiac death (4.8% vs. 4.8%, P=1.000), recurrent myocardial infarction (1.4% vs. 1.7%, P=0.619), target lesion revascularization (1.4% vs. 1.6%, P=0.737), target lesion failure (7.0% vs. 7.3%, P=0.752), and probable or definite stent thrombosis (0.5% vs. 0.9%, P=0.224) except for a trend toward lower incidence of target vessel revascularization (1.9% vs. 3.0%, P=0.087) and a lower rate of total major adverse cardiac events (9.3% vs. 11.9%, P=0.034) in the EES group.
CONCLUSIONS:
The present propensity score matched analysis performed in a large-scale, prospective, multicenter registry suggests that the second-generation drug-eluting stent EES has at least comparable or even better safety and efficacy profiles as compared with SES in the setting of AMI.
파일  C166.+Int+J+Cardiol.+2014;176(3)583-588..pdf (548.9K) DATE : 2021-05-26 11:43:23